Abstract:Studies from recent years have identified a diverse population of both bacteria and fungi in the human vagina and several community signatures have emerged that are associated with susceptibility to infectious disease. A healthy vaginal bacterial microbiome is most frequently dominated by Lactobacillus species [1], yet a combination of other genera are isolated in vaginal swabs in both healthy and diseased states. The vaginal fungal mycobiome is dominated by Ascomycota, of which Candida species are the most abundant. Approximately 20% to 30% of healthy human vaginal samples contain detectable Candida at a single time point, with nearly all of those being C . albicans , and 70% of the population is expected to be vaginally colonized with Candida longitudinally [2]. Despite its prevalence in the healthy vaginal mycobiome, C . albicans is the most common causative agent of vulvovaginal candidiasis (VVC), a cause of significant morbidity in the human population. The next most common species implicated in VVC is C . glabrata , while other species including C . lusitaniae , C . tropicalis , C . parapsilosis , and C . krusei are also known to contribute to vaginal infections [3–5]. Non- albicans Candida species are typically more resistant to antifungal drugs than C . albicans [6], complicating therapeutic options and increasing treatment timelines. A disease state is often distinguished by an exaggerated inflammatory response at the vaginal mucosa [3] that leads to vulvar pruritis and erythema [7]. Polymorphic Candida species can initiate the process of filamentation, morphogenesis from single-celled yeast to multicellular hyphae, which is typically accompanied by increased tissue damage and inflammation [8]. Microbial dysbiosis has long been associated with VVC due to the observation that antibiotic usage dramatically increases the risk of onset. This notion has been challenged by several population studies [9,10]; however, other studies have found a close association between Candida and specific bacteria as well as distinct Lactobacillus species that were associated with decreased observation of fungi in samples or symptomatic VVC [11–15]. Taken together, the evidence suggests that specific bacterial species can have complex impacts on fungal burden and symptomatic infection. Shifts in the vaginal microbiome are also associated with other genital tract infections [13,16] including bacterial vaginosis (BV) and aerobic vaginitis (AV), which are characterized by the displacement of Lactobacillus species by other bacteria such as Gardnerella vaginalis , Streptococcus agalactiae , Staphylococcus aureus , Escherichia coli , and Enterococcus faecalis [17]. Both BV and AV are polymicrobial in nature and are associated with concurrent Candida carriage in many cases [18,19]. Mixed vaginitis, which can include BV or AV together with VVC, is particularly difficult to treat, and during late stages of pregnancy can lead to severe adverse maternal and neonatal outcomes [17,20]. Because it is the most abundant fungal genus in the vagina, this review will focus on the interactions between Candida species and the healthy and pathogenic bacteria found in the vaginal environment. These interactions play a significant role in maintaining homeostasis as well as impacting disease pathogenesis in the genital tract (Fig 1).

Biofilm in Bacterial Vaginosis: A Legitimate Therapeutic Challenge?

Antibiofilm Agents for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Narrative Review

Bacterial Vaginosis and Vulvovaginal Candidiasis Pathophysiologic Interrelationship

Finding a Balance in the Vaginal Microbiome: How Do We Treat and Prevent the Occurrence of Bacterial Vaginosis?

Perspectives on Existing and Novel Alternative Intravaginal Probiotic Delivery Methods in the Context of Bacterial Vaginosis Infection

Non-antibiotic treatment of bacterial vaginosis—a systematic review

Molecular Analysis of the Diversity of Vaginal Microbiota Associated with Bacterial Vaginosis

The Restoration of the Vaginal Microbiota after Treatment for Bacterial Vaginosis with Metronidazole or Probiotics

The Antibiofilm Role of Biotics Family in Vaginal Fungal Infections

An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis

Mechanistic Insights into Immune Suppression and Evasion in Bacterial Vaginosis

Connecting the Dots: Translating the Vaginal Microbiome Into a Drug

The Female Vaginal Microbiome in Health and Bacterial Vaginosis

Selecting anti-microbial treatment of aerobic vaginitis

A Non-Antibiotic Antimicrobial Drug, a Biological Bacteriostatic Agent, is Useful for Treating Aerobic Vaginitis, Bacterial Vaginosis, and Vulvovaginal Candidiasis

Review on the etiology of bacterial vaginosis

An framework for the rational design of vaginal probiotic therapy

Polymicrobial consortia in the pathogenesis of biofilm vaginosis visualized by FISH. Historic review outlining the basic principles of the polymicrobial infection theory

Bacteria-responsive drug release platform for the local treatment of bacterial vaginosis

The Interplay Between Microbiota, Metabolites, Immunity During BV

Impact of interkingdom microbial interactions in the vaginal tract